Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial

Series C round co-led by R42 Group and Atomico, and joined by new/current investors; Financing to advance expanding rare disease pipeline U.S. FDA has cleared its investigational new drug (IND) application to advance HLX-1502 in Phase 2 clinical trial in NF1; Healx to initiate Phase 2 clinical trial by end of year Healx, co-founded by … Continued The post Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial appeared first on Healx .